Interview 10 Apr 2017 “Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec …a huge amount of research in lots of different directions. Alzheimer’s is kind of the last unclaimed franchise in big drug development. There is no disease-modifying drug for Alzheimer’s, period…. April 10, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 8 Jan 2018 Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease …as Phase III for Alzheimer’s treatment and Phase II for prevention in partnership with Genentech/Roche. The company has other antibodies and vaccines for Alzheimer’s, in addition to various other diseases…. January 8, 2018 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022 Watch: Norway’s Pre Diagnostics looks to early detection of Alzheimer’s Pre Diagnostics AS is a new Norwegian company developing and commercializing an innovative and effective diagnostic test for Alzheimer’s disease (AD). Founded by an experienced biotech team, Pre Diagnostics owns… December 22, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2023 Alzamend pushing ahead with Alzheimer’s vaccine trial Alzamend Neuro, Inc. has announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type. The purpose… April 4, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 Can MorphoSys’ Alzheimer’s Treatment Work Where Big Pharma has Failed? …brain may not be the most effective way to treat Alzheimer’s disease. Developing Alzheimer’s therapies has proven to be extremely difficult, with 30 failures counted for every treatment that is… March 15, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 9 Apr 2020 Two European Alzheimer’s Disease Treatments Show Promise in Phase II …of a vaccine halting the progress of Alzheimer’s. The vaccine is designed to treat Alzheimer’s by activating the immune system against harmful forms of a protein called tau, which is… April 9, 2020 - 4 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 FDA approves Alzheimer’s treatment …with early-stage Alzheimer’s a chance to pursue treatment that may slow progression of their disease.” The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the news. “This is encouraging news, and… July 7, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 13 Jun 2023 Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines …treatment of Alzheimer’s disease In September 2022, the monoclonal antibody lecanemab, which targets a toxic species of Abeta protein, slowed cognitive decline in early Alzheimer’s disease by approximately 30% in… June 13, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Podcast 12 Jan 2024 Could natural killer cells transform Alzheimer’s treatment? …a few months ago, I think that will be pretty dramatic.” Paul Song, CEO, NKGen Biotech Current challenges in Alzheimer’s treatment strategies NKGen took a different approach to tackling Alzheimer’s…. January 12, 2024 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2021 FDA Approval of Biogen’s Drug Boosts European Alzheimer’s Space The FDA shocked many life sciences observers by greenlighting Biogen’s treatment candidate for Alzheimer’s last week. Yet, for much of the Alzheimer’s disease community on both sides of the Atlantic,… June 17, 2021 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2023 Hope for Alzheimer’s patients after Lilly drug results …months. “These results demonstrate that diagnosing and treating people earlier in the course of Alzheimer’s disease may lead to greater clinical benefit,” said Liana Apostolova, distinguished professor in Alzheimer’s disease… July 17, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jul 2018 Swedish Alzheimer’s Treatment Slows the Disease in Phase II Trial BioArctic, based in Stockholm, has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial tested the antibody… July 9, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email